EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Alternative Splicing in Tumorigenesis and Cancer Therapy

Huiping Chen, Jingqun Tang, Juanjuan Xiang

Biomolecules · 29.05.2025 · 15 (6) · 789

DOI: 10.3390/biom15060789 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 29.05.2025. Verfasst von Huiping Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha 410013,…. Hauptthemen laut MEDLINE: Alternative Splicing, Neoplasms, Carcinogenesis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Hunan, National Natural Science Foundation of Changsha, National Natural Science Foundation of Hunan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alternative splicing (AS) is a pivotal post-transcriptional mechanism that expands the functional diversity of the proteome by enabling a single gene to generate multiple mRNA and protein isoforms. This process, which involves the differential inclusion or exclusion of exons and introns, is tightly regulated by splicing factors (SFs), such as serine/arginine-rich proteins (SRs), heterogeneous nuclear ribonucleoproteins (hnRNPs), and RNA-binding motif (RBM) proteins. These factors recognize specific sequences, including 5′ and 3′ splice sites and branch points, to ensure precise splicing. While AS is essential for normal cellular function, its dysregulation is increasingly implicated in cancer pathogenesis. Aberrant splicing can lead to the production of oncogenic isoforms that promote tumorigenesis, metastasis, and resistance to therapy. Furthermore, such abnormalities can cause the loss of tumor-suppressing activity, thereby contributing to cancer development. Importantly, abnormal AS events can generate neoantigens, which are presented on tumor cell surfaces via major histocompatibility complex (MHC) molecules, suggesting novel targets for cancer immunotherapy. Additionally, splice-switching oligonucleotides (SSOs) have shown promise as therapeutic agents because they modulate splicing patterns to restore normal gene function or induce tumor-suppressive isoforms. This review explores the mechanisms of AS dysregulation in cancer, its role in tumor progression, and its potential as a therapeutic target. We also discuss innovative technologies, such as high-throughput sequencing and computational approaches, that are revolutionizing the study of AS in cancer. Finally, we address the challenges and future prospects of targeting AS for personalized cancer therapies, emphasizing its potential in precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alternative SplicingNeoplasmsCarcinogenesisHumansAnimals

Stichwörter der Autor:innen

alternative splicingcancerimmunotherapyinnovative technologiesneoantigens

Autor:innen und Institutionen

  • Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha 410013, China.
  • Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha 410078, China.
  • NHC Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha 410078, China.
  • Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha 410013, China.

Förderung

  • Key Research and Development Program of Hunan
  • National Natural Science Foundation of Changsha
  • National Natural Science Foundation of Hunan

Zitieren

APA

Chen, H., Tang, J., & Xiang, J. (2025). Alternative Splicing in Tumorigenesis and Cancer Therapy. Biomolecules, 15(6), 789. https://doi.org/10.3390/biom15060789

Vancouver

Chen H, Tang J, Xiang J. Alternative Splicing in Tumorigenesis and Cancer Therapy. Biomolecules. 2025;15(6):789. doi:10.3390/biom15060789

BibTeX
@article{Chen2025,
  author = {Chen, Huiping and Tang, Jingqun and Xiang, Juanjuan},
  title = {Alternative Splicing in Tumorigenesis and Cancer Therapy},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {789},
  doi = {10.3390/biom15060789}
}
Kostenlos starten →